New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma

NEXT STORY
Immunicum AB (publ) Receives FDA Fast Track Designation for Ilixadencel in Gastrointestinal Stromal Tumors (GIST)
PREV STORY
New follow-up phase III data reinforce the long-term benefit of Roche’s Hemlibra for people with haemophilia A
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medtronic Receives IDE Approval to Initiate Study of IN.PACT® Admiral® Drug-Coated Balloon for a New Indication in Patients with End-Stage Renal Disease

DUBLIN - Jan. 26, 2017 - Medtronic plc (NYSE: MDT) today announced receipt of ...

author_avatar
NASDAQ Market News

Levitee Labs Announces Strategic Partnership with LiveRx Research Group to Provide Equitable Access to Hepatitis C Care throughout Alberta, Canada

author_avatar
NASDAQ Market News

Independence Blue Cross Foundation awards nearly $3.3 million in grants

PHILADELPHIA, Dec. 17, 2015 (GLOBE NEWSWIRE) -- The Independence Blue Cross Foundation (Foundation) today ...

author_avatar
NASDAQ Market News